Company: PolyPid Ltd.
Ticker: Nasdaq: PYPD
Sector: Healthcare
Investor Contact: Ben Shamsian

PolyPid News

News

PolyPid Announces Dikla Czaczkes Akselbrad Assumes Role of CEO

Company Previously Announced Planned CEO Transition Following Retirement of Amir WeisbergPETACH TIKVA, Israel, July 05, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, announced...

PolyPid to Present at the JMP Securities 2022 Life Sciences Conference

PETACH TIKVA, Israel, June 02, 2022 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the JMP Securities 2022 Life Sciences Conference, which is...

PolyPid Announces Publication of Animal Model Studies in 2022 ASCO Annual Meeting Abstract Demonstrating that Locally Administered OncoPLEX Potentially Decreases the Likelihood of Tumor Recurrence with Reduced Side Effects

Locally Administered Docetaxel Through Extended-Release Delivery via the Company's PLEX Technology Offers Potentially Enhanced Adjuvant Chemotherapy Option PETACH TIKVA, Israel, June 01, 2022 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage...

Skip to content